{
  "items": "39",
  "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
  "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
  "feed": [
    {
      "title": "Revelation Biosciences sets warrant expiration after stockholder approval",
      "url": "https://www.investing.com/news/sec-filings/revelation-biosciences-sets-warrant-expiration-after-stockholder-approval-93CH-4404041",
      "time_published": "20251211T160843",
      "authors": [
        "Investing.com"
      ],
      "summary": "Revelation Biosciences, Inc. (NASDAQ:REVB) has announced that the expiration date for its Class I Common Stock Warrants is now December 3, 2030, following stockholder approval. This approval allows the company to issue shares potentially exceeding 20% of its outstanding shares, providing crucial financing flexibility as the company manages significant cash burn. Concurrently, Revelation Biosciences continues to advance its clinical programs, including the submission of its end-of-phase 1 meeting package to the FDA for its Gemini treatment for acute kidney injury.",
      "banner_image": "https://i-invdn-com.investing.com/news/news_pile_69x52._800x533_L_1419494209.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.809025"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.719486"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.624966"
        }
      ],
      "overall_sentiment_score": 0.122892,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "REVB",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.100310",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting",
      "url": "https://www.heraldmailmedia.com/press-release/story/36718/revelation-biosciences-has-reached-a-quorum-for-its-december-3-2025-special-meeting/",
      "time_published": "20251204T140938",
      "authors": [
        "Revelation Biosciences",
        "Inc."
      ],
      "summary": "Revelation Biosciences (NASDAQ: REVB) announced it has reached a quorum for its December 3, 2025, Special Meeting and urged shareholders who haven't voted to do so by December 2. The company also highlighted recent progress, including the successful submission of its end-of-phase 1 meeting package to the FDA for Gemini as an acute kidney injury treatment and reported $9.6 million in gross proceeds from a September 2025 warrant inducement.",
      "banner_image": "https://www.heraldmailmedia.com/gciaf/prod/p?a=pageview&p=NTHM-TEALIUM-COBRAND&m=web&k=f14ebdd6-0569-4c64-af73-99937bc06379&s=noscript&",
      "source": "The Herald-Mail",
      "category_within_source": "General",
      "source_domain": "The Herald-Mail",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.943048"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "finance",
          "relevance_score": "0.611423"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.639219"
        }
      ],
      "overall_sentiment_score": 0.418807,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "REVB",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.426188",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Revelation Biosciences (NASDAQ: REVB) secures quorum ahead of Dec. 3 vote, notes $9.6M proceeds",
      "url": "https://www.stocktitan.net/news/REVB/revelation-biosciences-has-reached-a-quorum-for-its-december-3-2025-9dhlr98f0g83.html",
      "time_published": "20251204T140938",
      "authors": [
        "NULL"
      ],
      "summary": "Revelation Biosciences (NASDAQ: REVB) announced it has reached a quorum for its Special Meeting on December 3, 2025, with shareholders having until December 2, 2025, to submit votes. The company also reaffirmed regulatory progress with FDA acceptance of an end-of-phase 1 meeting package for Gemini in acute kidney injury and reported $9.6 million gross proceeds from a September 2025 warrant inducement. This news highlights the company's advancement in both governance and clinical development.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1112963",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.911466"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.823153"
        }
      ],
      "overall_sentiment_score": 0.1017,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "REVB",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.124379",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Revelation Biosciences shareholders approve warrant issuance and meeting adjournment By Investing.com",
      "url": "https://za.investing.com/news/sec-filings/revelation-biosciences-shareholders-approve-warrant-issuance-and-meeting-adjournment-93CH-4011928",
      "time_published": "20251204T044347",
      "authors": [],
      "summary": "Revelation Biosciences (NASDAQ:REVB) shareholders approved the reservation and issuance of common stock related to its Class I Common Stock Warrants at a special meeting. This approval sets the expiration date of the Class I Warrants to December 3, 2030, and also granted the company discretionary authority to adjourn the meeting if needed. CEO James Rolke provided a corporate update on product developments, coinciding with recent positive news regarding their Gemini treatment for acute kidney injury and chronic kidney disease.",
      "banner_image": "https://i-invdn-com.investing.com/news/international_newspapers_69x52._800x533_L_1419494241.jpg",
      "source": "Investing.com South Africa",
      "category_within_source": "General",
      "source_domain": "Investing.com South Africa",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.928862"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.723854"
        },
        {
          "topic": "finance",
          "relevance_score": "0.604825"
        }
      ],
      "overall_sentiment_score": 0.410157,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "REVB",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.429777",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting",
      "url": "https://heraldmailmedia.com/press-release/story/36718/revelation-biosciences-has-reached-a-quorum-for-its-december-3-2025-special-meeting/",
      "time_published": "20251204T044347",
      "authors": [
        "Revelation Biosciences",
        "Inc."
      ],
      "summary": "Revelation Biosciences, Inc. (NASDAQ:REVB) announced it has reached a quorum for its Special Meeting scheduled for December 3, 2025. The company urged remaining shareholders to vote by December 2, 2025, and highlighted recent progress including an end-of-phase 1 meeting package submission to the FDA and positive results from the PRIME clinical study. Revelation Biosciences is a clinical-stage life sciences company focused on rebalancing inflammation using its proprietary Gemini formulation.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1112963",
      "source": "The Herald-Mail",
      "category_within_source": "General",
      "source_domain": "The Herald-Mail",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.925889"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.901813"
        }
      ],
      "overall_sentiment_score": 0.140713,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "REVB",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.107914",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting",
      "url": "https://www.norwichbulletin.com/press-release/story/14565/revelation-biosciences-has-reached-a-quorum-for-its-december-3-2025-special-meeting/",
      "time_published": "20251203T160918",
      "authors": [
        "Revelation Biosciences",
        "Inc."
      ],
      "summary": "Revelation Biosciences (NASDAQ:REVB) has successfully reached a quorum for its Special Meeting scheduled for December 3, 2025. The company urges shareholders who have not yet voted to do so by December 2, 2025. This announcement follows recent positive developments including the submission of an end-of-phase 1 meeting package to the FDA and the reporting of key financial results for Q3 2025, which included $9.6 million from a warrant inducement.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1112963",
      "source": "Norwich Bulletin",
      "category_within_source": "General",
      "source_domain": "Norwich Bulletin",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.941041"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.705353"
        }
      ],
      "overall_sentiment_score": 0.48587,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "REVB",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.498254",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting",
      "url": "https://www.news-journalonline.com/press-release/story/14633/revelation-biosciences-has-reached-a-quorum-for-its-december-3-2025-special-meeting/",
      "time_published": "20251203T160918",
      "authors": [
        "Revelation Biosciences",
        "Inc."
      ],
      "summary": "Revelation Biosciences, Inc. (NASDAQ:REVB) announced it has reached a quorum for its Special Meeting scheduled for December 3, 2025, urging shareholders who haven't yet voted to do so by December 2, 2025. The company also provided updates on its end-of-phase 1 meeting package submission to the FDA for Gemini as a treatment for acute kidney injury and reported financial results, including $9.6 million from a warrant inducement.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1112963",
      "source": "Daytona Beach News-Journal",
      "category_within_source": "General",
      "source_domain": "Daytona Beach News-Journal",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.937543"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.807068"
        }
      ],
      "overall_sentiment_score": 0.214032,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "REVB",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.207531",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting",
      "url": "https://www.cincinnati.com/press-release/story/14280/revelation-biosciences-has-reached-a-quorum-for-its-december-3-2025-special-meeting/",
      "time_published": "20251203T160918",
      "authors": [
        "Revelation Biosciences",
        "Inc."
      ],
      "summary": "Revelation Biosciences, Inc. announced it has reached a quorum for its Special Meeting scheduled for December 3, 2025, and encourages remaining shareholders to vote by December 2, 2025. The company also highlighted recent progress, including submitting an end-of-phase 1 meeting package to the FDA for Gemini as a treatment for acute kidney injury and reporting Q3 2025 financial results with $9.6 million from warrant inducement.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1112963",
      "source": "Cincinnati Enquirer",
      "category_within_source": "General",
      "source_domain": "Cincinnati Enquirer",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.819454"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.730420"
        }
      ],
      "overall_sentiment_score": 0.241495,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "REVB",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.225582",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting",
      "url": "https://www.yorkdispatch.com/press-release/story/13230/revelation-biosciences-has-reached-a-quorum-for-its-december-3-2025-special-meeting/",
      "time_published": "20251203T131003",
      "authors": [
        "Revelation Biosciences",
        "Inc."
      ],
      "summary": "Revelation Biosciences, a clinical-stage life sciences company, announced it has successfully reached a quorum for its Special Meeting scheduled for December 3, 2025. The company encouraged shareholders who haven't yet voted to do so by December 2, 2025. This follows recent developments including the submission of an end-of-phase 1 meeting package to the FDA for Gemini, a treatment for acute kidney injury, and the reporting of financial results with $9.6 million in warrant inducement.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1112963",
      "source": "York Dispatch",
      "category_within_source": "General",
      "source_domain": "York Dispatch",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.906940"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.818405"
        }
      ],
      "overall_sentiment_score": 0.313775,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "REVB",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.333433",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting",
      "url": "https://www.vcstar.com/press-release/story/13155/revelation-biosciences-has-reached-a-quorum-for-its-december-3-2025-special-meeting/",
      "time_published": "20251203T131003",
      "authors": [
        "Revelation Biosciences",
        "Inc."
      ],
      "summary": "Revelation Biosciences, Inc. (NASDAQ:REVB) announced it has successfully reached a quorum for its Special Meeting scheduled for December 3, 2025. The company is encouraging all shareholders who have not yet voted to do so by 11:59 PM ET on December 2, 2025. This announcement follows recent updates on their successful submission of an end-of-phase 1 meeting package to the FDA and the reporting of their Q3 2025 financial results, including $9.6 million from warrant inducement.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1112963",
      "source": "Ventura County Star",
      "category_within_source": "General",
      "source_domain": "Ventura County Star",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.910028"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.838156"
        },
        {
          "topic": "finance",
          "relevance_score": "0.746384"
        }
      ],
      "overall_sentiment_score": 0.115285,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "REVB",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.129729",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Revelation Biosciences shareholders approve warrant issuance and meeting adjournment",
      "url": "https://www.investing.com/news/sec-filings/revelation-biosciences-shareholders-approve-warrant-issuance-and-meeting-adjournment-93CH-4389639",
      "time_published": "20251202T150849",
      "authors": [
        "Investing.com"
      ],
      "summary": "Revelation Biosciences shareholders have approved the reservation and issuance of common stock related to its Class I Common Stock Warrants, extending their expiration to December 3, 2030. This decision, made at a special meeting, also granted discretionary authority to adjourn the meeting if needed. Additionally, CEO James Rolke provided a corporate update, and the company recently submitted an end-of-phase 1 meeting package to the FDA for its Gemini treatment for acute kidney injury, which had previously met safety endpoints in a Phase 1b study for chronic kidney disease.",
      "banner_image": "https://i-invdn-com.investing.com/news/World_News_10_800x533_L_1420026292.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.805762"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.704127"
        }
      ],
      "overall_sentiment_score": 0.462199,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "REVB",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.459939",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year",
      "url": "https://www.providencejournal.com/press-release/story/12468/revelation-biosciences-on-track-for-end-of-phase-1-meeting-with-fda-later-this-year/",
      "time_published": "20251124T044347",
      "authors": [
        "Revelation Biosciences",
        "Inc."
      ],
      "summary": "Revelation Biosciences (NASDAQ:REVB) has successfully submitted and had accepted its end-of-phase 1 meeting package to the FDA and is on track for a meeting later this year. This meeting aims to gain agency feedback on the clinical development and regulatory pathway for Gemini, a treatment for acute kidney injury (AKI). The company previously announced positive safety and activity data from its Phase 1b PRIME clinical study, demonstrating Gemini's potential to significantly reduce inflammatory activity.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1105050",
      "source": "The Providence Journal",
      "category_within_source": "General",
      "source_domain": "The Providence Journal",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.915213"
        },
        {
          "topic": "finance",
          "relevance_score": "0.624139"
        }
      ],
      "overall_sentiment_score": 0.621768,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "REVB",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.645736",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year",
      "url": "https://www.tuscaloosanews.com/press-release/story/9302/revelation-biosciences-on-track-for-end-of-phase-1-meeting-with-fda-later-this-year/",
      "time_published": "20251121T160843",
      "authors": [
        "Revelation Biosciences",
        "Inc."
      ],
      "summary": "Revelation Biosciences (NASDAQ: REVB) announced the successful submission and acceptance of their end-of-phase 1 meeting package to the FDA, and are on track to meet with the agency later this year. The meeting aims to gather feedback on the clinical development and regulatory pathway for Gemini, a potential treatment for acute kidney injury (AKI). This follows positive safety and activity data from their Phase 1b PRIME clinical study in chronic kidney disease patients, demonstrating Gemini's ability to reduce inflammation and restore normal cellular response.",
      "banner_image": "https://app.accessnewswire.com/imagelibrary/35e0e8b8-3b89-4fc4-91c8-5544d82d9d94/1105050/image.png",
      "source": "The Tuscaloosa News",
      "category_within_source": "General",
      "source_domain": "The Tuscaloosa News",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.935613"
        }
      ],
      "overall_sentiment_score": 0.445348,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "REVB",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.429094",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record Date",
      "url": "https://www.savannahnow.com/press-release/story/9885/revelation-biosciences-inc-announces-cancellation-of-adjournment-of-october-29-2025-special-meeting-of-stockholders-and-new-record-date/",
      "time_published": "20251121T130918",
      "authors": [
        "Revelation Biosciences",
        "Inc."
      ],
      "summary": "Revelation Biosciences Inc. announced the cancellation of its October 29, 2025 Special Meeting of Stockholders due to technical difficulties preventing stockholders from voting all their shares. A new record date of October 29, 2025, has been set for a new Special Meeting scheduled for December 3, 2025. The company will issue new proxy materials and encourages prompt stockholder voting.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1092978",
      "source": "Savannah Morning News",
      "category_within_source": "General",
      "source_domain": "Savannah Morning News",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.823143"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.916270"
        }
      ],
      "overall_sentiment_score": 0.036667,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "REVB",
          "relevance_score": "0.329029",
          "ticker_sentiment_score": "0.038007",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record Date",
      "url": "https://www.hutchnews.com/press-release/story/46160/revelation-biosciences-inc-announces-cancellation-of-adjournment-of-october-29-2025-special-meeting-of-stockholders-and-new-record-date/",
      "time_published": "20251109T170857",
      "authors": [
        "Revelation Biosciences",
        "Inc."
      ],
      "summary": "Revelation Biosciences Inc. announced the cancellation of its special meeting of stockholders initially scheduled for October 15, 2025, and adjourned to October 29, 2025, due to technical difficulties preventing stockholders from fully voting their shares. The company has set a new record date of October 29, 2025, for a new Special Meeting of Stockholders to be held on December 3, 2025, and will issue new proxy materials. Revelation Biosciences is a clinical-stage life sciences company focusing on rebalancing inflammation with its proprietary formulation Gemini.",
      "banner_image": "NULL",
      "source": "The Hutchinson News",
      "category_within_source": "General",
      "source_domain": "The Hutchinson News",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.928265"
        },
        {
          "topic": "finance",
          "relevance_score": "0.738728"
        }
      ],
      "overall_sentiment_score": 0.023906,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "REVB",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.042392",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025",
      "url": "https://www.news-journalonline.com/press-release/story/9764/revelation-biosciences-inc-announces-adjournment-of-october-15-2025-special-meeting-of-stockholders-to-october-29-2025/",
      "time_published": "20251109T170857",
      "authors": [
        "Revelation Biosciences",
        "Inc."
      ],
      "summary": "Revelation Biosciences Inc. has adjourned its Special Meeting of Stockholders from October 15, 2025, to October 29, 2025, due to insufficient shares present. The meeting will reconvene virtually at 12:00 p.m. ET, and stockholders are encouraged to vote by the new date. The record date of September 11, 2025, remains unchanged.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1087448",
      "source": "Daytona Beach News-Journal",
      "category_within_source": "General",
      "source_domain": "Daytona Beach News-Journal",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.908693"
        }
      ],
      "overall_sentiment_score": 0.04383,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "REVB",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.024783",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record Date",
      "url": "https://www.gadsdentimes.com/press-release/story/57848/revelation-biosciences-inc-announces-cancellation-of-adjournment-of-october-29-2025-special-meeting-of-stockholders-and-new-record-date/",
      "time_published": "20251108T044347",
      "authors": [
        "Revelation Biosciences",
        "Inc."
      ],
      "summary": "Revelation Biosciences Inc. announced the cancellation of its October 29, 2025 Special Meeting of Stockholders due to technical difficulties preventing stockholders from voting all their shares. The company has set a new record date of October 29, 2025, for a new Special Meeting to be held on December 3, 2025, and will issue new proxy materials to record stockholders. Revelation Biosciences is a clinical-stage life sciences company focused on rebalancing inflammation with its proprietary Gemini formulation.",
      "banner_image": "NULL",
      "source": "Gadsden Times",
      "category_within_source": "General",
      "source_domain": "Gadsden Times",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.804687"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.932032"
        }
      ],
      "overall_sentiment_score": -0.051256,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "REVB",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.081847",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025",
      "url": "https://www.greenbaypressgazette.com/press-release/story/69475/revelation-biosciences-inc-announces-adjournment-of-october-15-2025-special-meeting-of-stockholders-to-october-29-2025/",
      "time_published": "20251108T044347",
      "authors": [
        "Revelation Biosciences",
        "Inc."
      ],
      "summary": "Revelation Biosciences Inc. (NASDAQ:REVB) has adjourned its Special Meeting of Stockholders from October 15, 2025, to October 29, 2025, due to insufficient shares present. The company encourages all stockholders to vote in advance of the new meeting date. The record date of September 11, 2025, remains unchanged, and the meeting will reconvene virtually.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1087448",
      "source": "Green Bay Press-Gazette",
      "category_within_source": "General",
      "source_domain": "Green Bay Press-Gazette",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.947041"
        },
        {
          "topic": "finance",
          "relevance_score": "0.740306"
        }
      ],
      "overall_sentiment_score": 0.011225,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "REVB",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.030680",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025",
      "url": "https://www.vvdailypress.com/press-release/story/8195/revelation-biosciences-inc-announces-adjournment-of-october-15-2025-special-meeting-of-stockholders-to-october-29-2025/",
      "time_published": "20251108T044347",
      "authors": [
        "Revelation Biosciences",
        "Inc."
      ],
      "summary": "Revelation Biosciences Inc. (NASDAQ:REVB) has announced the adjournment of its 2025 Special Meeting of Stockholders, originally scheduled for October 15, 2025, to October 29, 2025. This decision was made due to insufficient shares present at the initial meeting, aiming to provide additional time for shareholders to cast their votes. The meeting will reconvene virtually, and the record date of September 11, 2025, remains unchanged.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1087448",
      "source": "Victorville Daily Press",
      "category_within_source": "General",
      "source_domain": "Victorville Daily Press",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.933198"
        },
        {
          "topic": "finance",
          "relevance_score": "0.704857"
        }
      ],
      "overall_sentiment_score": 0.041563,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "REVB",
          "relevance_score": "0.304943",
          "ticker_sentiment_score": "0.044920",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025 - Shreveport Times",
      "url": "https://www.shreveporttimes.com/press-release/story/8342/revelation-biosciences-inc-announces-adjournment-of-october-15-2025-special-meeting-of-stockholders-to-october-29-2025/",
      "time_published": "20251016T070358",
      "authors": [
        "Revelation Biosciences",
        "Inc."
      ],
      "summary": "Revelation Biosciences Inc. has announced the adjournment of its Special Meeting of Stockholders from October 15, 2025, to October 29, 2025, at 12:00 p.m. Eastern Time, to be held virtually. The record date of September 11, 2025, remains unchanged, and stockholders who have not yet voted are encouraged to do so. The company emphasizes the importance of stockholder participation and voting, with further information available through its proxy solicitor, Advantage Proxy.",
      "banner_image": null,
      "source": "Shreveport Times",
      "category_within_source": "General",
      "source_domain": "Shreveport Times",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.822721"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.748455"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.637239"
        }
      ],
      "overall_sentiment_score": 0.041411,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "REVB",
          "relevance_score": "0.347687",
          "ticker_sentiment_score": "0.048225",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025 - The Desert Sun",
      "url": "https://www.desertsun.com/press-release/story/62370/revelation-biosciences-inc-announces-adjournment-of-october-15-2025-special-meeting-of-stockholders-to-october-29-2025/",
      "time_published": "20251016T062832",
      "authors": [
        "Revelation Biosciences",
        "Inc."
      ],
      "summary": "Revelation Biosciences Inc. announced the adjournment of its Special Meeting of Stockholders from October 15, 2025, to October 29, 2025, at 12:00 p.m. Eastern Time, to be held virtually. The record date of September 11, 2025, remains unchanged, and stockholders who have not yet voted are encouraged to do so. The company urges all stockholders to participate and exercise their right to vote before the new meeting date.",
      "banner_image": null,
      "source": "The Desert Sun",
      "category_within_source": "General",
      "source_domain": "The Desert Sun",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "finance",
          "relevance_score": "0.741919"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.631487"
        }
      ],
      "overall_sentiment_score": 0.018659,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "REVB",
          "relevance_score": "0.331571",
          "ticker_sentiment_score": "0.005722",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025 - The Courier-Journal",
      "url": "https://www.courier-journal.com/press-release/story/113471/revelation-biosciences-inc-announces-adjournment-of-october-15-2025-special-meeting-of-stockholders-to-october-29-2025/",
      "time_published": "20251016T034333",
      "authors": [
        "Revelation Biosciences",
        "Inc."
      ],
      "summary": "Revelation Biosciences Inc. has announced the adjournment of its Special Meeting of Stockholders from October 15, 2025, to October 29, 2025, at 12:00 p.m. Eastern Time, to be held virtually. The record date of September 11, 2025, remains unchanged, and stockholders who have not yet voted are encouraged to do so. The company, a clinical-stage life sciences firm focusing on rebalancing inflammation with its Gemini formulation, emphasizes the importance of stockholder participation in the meeting.",
      "banner_image": null,
      "source": "The Courier-Journal",
      "category_within_source": "General",
      "source_domain": "The Courier-Journal",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.706668"
        }
      ],
      "overall_sentiment_score": 0.024774,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "REVB",
          "relevance_score": "0.332591",
          "ticker_sentiment_score": "0.037153",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025 - The Clarion-Ledger",
      "url": "https://www.clarionledger.com/press-release/story/89032/revelation-biosciences-inc-announces-adjournment-of-october-15-2025-special-meeting-of-stockholders-to-october-29-2025/",
      "time_published": "20251016T031547",
      "authors": [
        "Revelation Biosciences",
        "Inc."
      ],
      "summary": "Revelation Biosciences Inc. has announced the adjournment of its Special Meeting of Stockholders from October 15, 2025, to October 29, 2025, at 12:00 p.m. ET, held virtually. The record date of September 11, 2025, remains unchanged, and stockholders are encouraged to vote if they haven't already. The company emphasizes the importance of stockholder participation and voting.",
      "banner_image": null,
      "source": "The Clarion-Ledger",
      "category_within_source": "General",
      "source_domain": "The Clarion-Ledger",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.741107"
        },
        {
          "topic": "finance",
          "relevance_score": "0.638425"
        }
      ],
      "overall_sentiment_score": 0.021042,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "REVB",
          "relevance_score": "0.306104",
          "ticker_sentiment_score": "0.044765",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Revelation Biosciences Adjourns Special Stockholders Meeting - TipRanks",
      "url": "https://www.tipranks.com/news/company-announcements/revelation-biosciences-adjourns-special-stockholders-meeting",
      "time_published": "20251015T212734",
      "authors": [
        "TipRanks Auto-Generated Newsdesk"
      ],
      "summary": "Revelation Biosciences (REVB) announced the adjournment of its Special Meeting of Stockholders to October 29, 2025, due to a lack of quorum, urging all stockholders to participate and vote. The company faces significant financial challenges, including no revenue and persistent losses, leading TipRanks' AI Analyst Spark to rate REVB as \"Underperform.\" Revelation Biosciences is a clinical-stage life sciences company focused on inflammation rebalancing.",
      "banner_image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_2127549605-750x406.jpg",
      "source": "TipRanks",
      "category_within_source": "General",
      "source_domain": "TipRanks",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.718118"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.613517"
        },
        {
          "topic": "finance",
          "relevance_score": "0.409338"
        }
      ],
      "overall_sentiment_score": 0.005158,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "REVB",
          "relevance_score": "0.339757",
          "ticker_sentiment_score": "0.036228",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Revelation Biosciences Inc Adjourns Special Meeting to October 29, 2025 - TradingView",
      "url": "https://www.tradingview.com/news/tradingview:06bcb9881c729:0-revelation-biosciences-inc-adjourns-special-meeting-to-october-29-2025/",
      "time_published": "20251015T211501",
      "authors": [],
      "summary": "Revelation Biosciences Inc. announced the adjournment of its Special Meeting of Stockholders to October 29, 2025. The meeting was postponed due to a lack of quorum, and stockholders are encouraged to vote before the new date. The record date of September 11, 2025, remains unchanged, and the meeting will be held virtually.",
      "banner_image": null,
      "source": "TradingView",
      "category_within_source": "General",
      "source_domain": "TradingView",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.808012"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.725741"
        }
      ],
      "overall_sentiment_score": 0.007475,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "REVB",
          "relevance_score": "0.328882",
          "ticker_sentiment_score": "0.030438",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025",
      "url": "https://www.corsicanadailysun.com/national/revelation-biosciences-inc-announces-adjournment-of-october-15-2025-special-meeting-of-stockholders-to-october/article_03433750-1f35-57d6-a598-6edfb0800b8f.html",
      "time_published": "20251015T210210",
      "authors": [
        "ACCESS Newswire"
      ],
      "summary": "Revelation Biosciences Inc. has announced the adjournment of its Special Meeting of Stockholders from October 15, 2025, to October 29, 2025, at 12:00 p.m. Eastern Time. The meeting will continue to be held virtually, and the record date of September 11, 2025, remains unchanged. Stockholders who have already voted do not need to take further action, while those who have not are encouraged to vote by the new meeting date.",
      "banner_image": null,
      "source": "Corsicana Daily Sun",
      "category_within_source": "General",
      "source_domain": "Corsicana Daily Sun",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.813902"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.718003"
        }
      ],
      "overall_sentiment_score": 0.046287,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "REVB",
          "relevance_score": "0.329894",
          "ticker_sentiment_score": "0.012571",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Oct 29, 2025 reconvene \u2014 Revelation Biosciences adjourns special meeting; record date unchanged - Stock Titan",
      "url": "https://www.stocktitan.net/news/REVB/revelation-biosciences-inc-announces-adjournment-of-october-15-2025-ki9nt0kp5a51.html",
      "time_published": "20251015T210000",
      "authors": [],
      "summary": "Revelation Biosciences (NASDAQ:REVB) announced the adjournment of its October 15, 2025 Special Meeting of Stockholders due to insufficient shares present. The meeting will reconvene on October 29, 2025, at 12:00 p.m. ET, and the record date of September 11, 2025, remains unchanged. Stockholders who have not yet voted are encouraged to do so, while those who have already voted need not take further action unless they wish to change their vote.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.806285"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.732180"
        }
      ],
      "overall_sentiment_score": 0.015409,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "REVB",
          "relevance_score": "0.329010",
          "ticker_sentiment_score": "0.004833",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025",
      "url": "https://www.providencejournal.com/press-release/story/8325/revelation-biosciences-inc-announces-adjournment-of-october-15-2025-special-meeting-of-stockholders-to-october-29-2025/",
      "time_published": "20251015T150918",
      "authors": [
        "Revelation Biosciences",
        "Inc."
      ],
      "summary": "Revelation Biosciences Inc. announced the adjournment of its 2025 Special Meeting of Stockholders from October 15, 2025, to October 29, 2025, due to insufficient shares being present. The meeting will reconvene virtually at 12:00 p.m. Eastern Time, and stockholders who have not yet voted are encouraged to do so. The record date of September 11, 2025, remains unchanged.",
      "banner_image": "https://www.providencejournal.com/gciaf/prod/p?a=pageview&p=NPRJ-TEALIUM-COBRAND&m=web&k=f14ebdd6-0569-4c64-af73-99937bc06379&s=noscript&",
      "source": "The Providence Journal",
      "category_within_source": "General",
      "source_domain": "The Providence Journal",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.938968"
        },
        {
          "topic": "finance",
          "relevance_score": "0.728043"
        }
      ],
      "overall_sentiment_score": 0.045566,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "REVB",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.020237",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025",
      "url": "https://www.southcoasttoday.com/press-release/story/8270/revelation-biosciences-inc-announces-adjournment-of-october-15-2025-special-meeting-of-stockholders-to-october-29-2025/",
      "time_published": "20251015T130859",
      "authors": [
        "Revelation Biosciences",
        "Inc."
      ],
      "summary": "Revelation Biosciences Inc. announced the adjournment of its 2025 Special Meeting of Stockholders from October 15, 2025, to October 29, 2025, due to insufficient shares present. The meeting will reconvene virtually at 12:00 p.m., Eastern Time, on the new date, with the record date of September 11, 2025, remaining unchanged. The company encourages all stockholders to vote on the proposals outlined in the proxy materials.",
      "banner_image": "NULL",
      "source": "SouthCoastToday.com",
      "category_within_source": "General",
      "source_domain": "SouthCoastToday.com",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.844139"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.707695"
        }
      ],
      "overall_sentiment_score": 0.029477,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "REVB",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.019852",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025",
      "url": "https://www.pnj.com/press-release/story/9639/revelation-biosciences-inc-announces-adjournment-of-october-15-2025-special-meeting-of-stockholders-to-october-29-2025/",
      "time_published": "20251015T120944",
      "authors": [
        "Revelation Biosciences",
        "Inc."
      ],
      "summary": "Revelation Biosciences Inc. announced the adjournment of its 2025 Special Meeting of Stockholders, originally scheduled for October 15, 2025, to October 29, 2025, due to insufficient shares present. This adjournment allows additional time for stockholders to vote on proposals outlined in the Company's proxy materials. The meeting will still be held virtually, and the record date remains September 11, 2025.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1087448",
      "source": "Pensacola News Journal",
      "category_within_source": "General",
      "source_domain": "Pensacola News Journal",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.925183"
        },
        {
          "topic": "finance",
          "relevance_score": "0.712463"
        }
      ],
      "overall_sentiment_score": 0.094155,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "REVB",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.087088",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Revelation Biosciences (NASDAQ:REVB) Receives \u201cSell (E)\u201d Rating from Weiss Ratings - Defense World",
      "url": "https://www.defenseworld.net/2025/10/15/revelation-biosciences-nasdaqrevb-receives-sell-e-rating-from-weiss-ratings.html",
      "time_published": "20251015T073418",
      "authors": [
        "Defense World Staff"
      ],
      "summary": "Revelation Biosciences (NASDAQ:REVB) has received a \"Sell (E)\" rating from Weiss Ratings in a recent research note. The company is a clinical-stage biopharmaceutical firm focused on developing immune system therapeutics and diagnostics, including candidates for surgical site infection, acute kidney injury, and chronic kidney disease. Investors can sign up to receive daily alerts on Revelation Biosciences and related companies.",
      "banner_image": null,
      "source": "Defense World",
      "category_within_source": "General",
      "source_domain": "Defense World",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.828381"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.712988"
        }
      ],
      "overall_sentiment_score": 0.031732,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "REVB",
          "relevance_score": "0.334537",
          "ticker_sentiment_score": "0.048384",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025",
      "url": "https://www.hillsdale.net/press-release/story/53808/revelation-biosciences-inc-announces-financial-results-for-the-three-and-nine-months-ended-september-30-2025/",
      "time_published": "20250930T044347",
      "authors": [
        "Revelation Biosciences",
        "Inc."
      ],
      "summary": "Revelation Biosciences, Inc. reported its financial results for the three and nine months ended September 30, 2025, highlighting groundbreaking top-line results from its PRIME clinical study and gross proceeds of $9.6 million from a warrant inducement. The company had $12.7 million in cash and equivalents, sufficient to fund operations through Q3 2026, and is advancing its Gemini program for various inflammatory conditions, including acute and chronic kidney disease. Net loss for the nine months ended September 30, 2025, was $6.4 million.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1097873",
      "source": "Hillsdale Daily News",
      "category_within_source": "General",
      "source_domain": "Hillsdale Daily News",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.909367"
        }
      ],
      "overall_sentiment_score": 0.323149,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "REVB",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.308227",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds",
      "url": "https://www.commercialappeal.com/press-release/story/40785/revelation-biosciences-inc-announces-exercise-of-warrants-for-9-6-million-in-gross-proceeds/",
      "time_published": "20250916T130910",
      "authors": [
        "accesswire"
      ],
      "summary": "Revelation Biosciences Inc. (NASDAQ: REVB) announced the immediate exercise of certain outstanding warrants, generating $9.6 million in gross proceeds. The exercise involved 4,355,000 shares at $2.20 per share, with new Class I warrants issued to exercising holders for future common stock purchases. The company is a clinical-stage life sciences firm focused on rebalancing inflammation with its Gemini formulation.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1071656",
      "source": "The Commercial Appeal",
      "category_within_source": "General",
      "source_domain": "The Commercial Appeal",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.944793"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.832533"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.716402"
        }
      ],
      "overall_sentiment_score": 0.402951,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "REVB",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.439441",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Revelation Biosciences Stock Slides 17% After Company Reports 3 Severe Adverse Events In Early Stage Trial Of Inflammation Drug",
      "url": "https://stocktwits.com/news-articles/markets/equity/revelation-biosciences-stock-slides-after-company-reports-three-severe-adverse-events-in-early-stage-trial-of-inflammation-drug/chwK9BBRdt8",
      "time_published": "20250909T123100",
      "authors": [
        "Anan Ashraf"
      ],
      "summary": "Revelation Biosciences (REVB) stock dropped 17% after the company reported three severe adverse events (chills, nausea, vomiting) at the highest dose of its investigational drug Gemini, despite resolving within three hours. The firm also announced positive safety and activity data from the early-stage trial in chronic kidney disease patients, noting that Gemini significantly reduced inflammatory activity and restored normal cellular response. CEO James Rolke believes Gemini could be a \"game-changer\" for inflammation treatment, and the company plans to meet with the FDA to discuss program advancement.",
      "banner_image": "https://news.stocktwits-cdn.com/large_Getty_Images_1445160636_jpg_9759816169.webp",
      "source": "Stocktwits",
      "category_within_source": "General",
      "source_domain": "Stocktwits",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.916896"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.827739"
        }
      ],
      "overall_sentiment_score": -0.285006,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "REVB",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.297774",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study",
      "url": "https://finance.yahoo.com/news/revelation-biosciences-inc-completes-dosing-130000405.html",
      "time_published": "20250716T160843",
      "authors": [
        "NULL"
      ],
      "summary": "Revelation Biosciences Inc. announced the completion of patient dosing in its PRIME Phase 1b clinical study for intravenously administered Gemini in patients with Stage 3 and 4 Chronic Kidney Disease (CKD). The study enrolled 5 cohorts across 3 clinics in the U.S., and data, including safety parameters and biomarkers of activity, is expected during Q3 2025. Gemini is a proprietary formulation aimed at rebalancing inflammation and is being developed for various indications, including preventing acute kidney injury and treating chronic kidney disease.",
      "banner_image": "https://s.yimg.com/ny/api/res/1.2/dHE396X1M1w0Zv1ePeyEm1Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTkwMDtoPTM2MA--/https://s.yimg.com/os/creatr-uploaded-images/2020-11/29c0c440-2a63-11eb-aff7-af8d7ebd46a4.cf.webp",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.929051"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.621043"
        }
      ],
      "overall_sentiment_score": 0.447764,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "REVB",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.441332",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study",
      "url": "https://www.businesswire.com/news/home/20250715204957/en/Revelation-Biosciences-Inc.-Completes-Dosing-of-Patients-in-PRIME-Study",
      "time_published": "20250716T120944",
      "authors": [
        "NULL"
      ],
      "summary": "Revelation Biosciences, Inc. announced the completion of patient dosing in its PRIME Phase 1b clinical study for Gemini, targeting Stage 3 and 4 Chronic Kidney Disease. The study enrolled 5 cohorts across 3 U.S. clinics, with data expected during Q3 2025 that will include safety parameters, hematologic changes, and inflammatory response evaluation. The company looks forward to sharing the study results and engaging with the FDA for future clinical development and approval pathways later this year.",
      "banner_image": "https://mms.businesswire.com/media/20250715204957/en/839057/4/revelation.jpg",
      "source": "Business Wire",
      "category_within_source": "General",
      "source_domain": "Business Wire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.817412"
        }
      ],
      "overall_sentiment_score": 0.408222,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "REVB",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.437364",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Revelation Biosciences, Inc. (REVB) Raises $4M in Public Offering",
      "url": "https://finance.yahoo.com/news/revelation-biosciences-inc-revb-raises-025600633.html",
      "time_published": "20250529T044347",
      "authors": [
        "Laiba Immad"
      ],
      "summary": "Revelation Biosciences, Inc. (NASDAQ: REVB), a clinical-stage life sciences company, has successfully completed a public offering, securing approximately $4 million in gross proceeds. The offering involved 3,640,000 shares of common stock (or equivalents) and warrants to purchase up to 14,560,000 shares, all priced at $1.10 per share and warrant. The company intends to utilize these proceeds for advancing its clinical and preclinical programs, including completing a Phase 1b clinical trial and developing new products.",
      "banner_image": "NULL",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.907603"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.824441"
        },
        {
          "topic": "finance",
          "relevance_score": "0.743128"
        }
      ],
      "overall_sentiment_score": 0.34244,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "REVB",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.312776",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Revelation Biosciences announces warrant exercise and inducement",
      "url": "https://www.investing.com/news/company-news/revelation-biosciences-announces-warrant-exercise-and-inducement-93CH-3587661",
      "time_published": "20240826T164200",
      "authors": [
        "Investing.com"
      ],
      "summary": "Revelation Biosciences has entered into agreements with warrant holders to exercise Class D Common Stock Warrants for approximately 2.5 million shares at a reduced price of $1.50 per share, generating around $3.8 million. The funds will support ongoing clinical trials for product candidates like GEM-AKI, GEM-CKD, and GEM-PSI, as well as manufacturing for a clinical batch of Gemini. This strategic move aims to strengthen the company's financial position amidst recent challenges including potential Nasdaq delisting and a court judgment for unpaid fees.",
      "banner_image": null,
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.837891"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.735447"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.623526"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.634448"
        }
      ],
      "overall_sentiment_score": -0.213565,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "REVB",
          "relevance_score": "0.961807",
          "ticker_sentiment_score": "-0.211681",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Revelation Biosciences faces Nasdaq delisting over equity deficit",
      "url": "https://www.investing.com/news/company-news/revelation-biosciences-faces-nasdaq-delisting-over-equity-deficit-93CH-3578072",
      "time_published": "20240819T162800",
      "authors": [
        "Investing.com"
      ],
      "summary": "Revelation Biosciences is facing delisting from The Nasdaq Capital Market due to non-compliance with the minimum stockholders' equity rule, reporting only $1.14 million against the required $2.5 million. The company has 45 days to submit a compliance plan, and although its stock and warrants continue to trade, significant financial challenges and analyst skepticism about profitability persist. This comes amid a recent court judgment of $7.3 million and adjustments to its warrant exercise prices, despite positive Phase 1 trial results for its drug Gemini.",
      "banner_image": null,
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.926648"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.842594"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.724249"
        },
        {
          "topic": "finance",
          "relevance_score": "0.615701"
        }
      ],
      "overall_sentiment_score": -0.605046,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "REVB",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.609911",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    }
  ]
}